Cargando…

Novel oral histone deacetylase inhibitor, MPT0E028, displays potent growth-inhibitory activity against human B-cell lymphoma in vitro and in vivo

Histone deacetylase (HDAC) inhibitor has been a promising therapeutic option in cancer therapy due to its ability to induce growth arrest, differentiation, and apoptosis. In this study, we demonstrated that MPT0E028, a novel HDAC inhibitor, reduces the viability of B-cell lymphomas by inducing apopt...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Han-Li, Peng, Chieh-Yu, Lai, Mei-Jung, Chen, Chun-Han, Lee, Hsueh-Yun, Wang, Jing-Chi, Liou, Jing-Ping, Pan, Shiow-Lin, Teng, Che-Ming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2014
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467128/ https://www.ncbi.nlm.nih.gov/pubmed/25669976

Ejemplares similares

Anticancer Activity of MPT0E028, a Novel Potent Histone Deacetylase Inhibitor, in Human Colorectal Cancer HCT116 Cells In Vitro and In Vivo
por: Huang, Han-Lin, et al.
Publicado: (2012)

Correction: Anticancer Activity of MPT0E028, a Novel Potent Histone Deacetylase Inhibitor, in Human Colorectal Cancer HCT116 Cells In Vitro and In Vivo
por: Huang, Han-Li, et al.
Publicado: (2012)

A Potent Histone Deacetylase Inhibitor MPT0E028 Mitigates Emphysema Severity via Components of the Hippo Signaling Pathway in an Emphysematous Mouse Model
por: Yeh, Lu-Yang, et al.
Publicado: (2022)

Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status
por: Chao, Min-Wu, et al.
Publicado: (2019)

Preclinical anti-arthritic study and pharmacokinetic properties of a potent histone deacetylase inhibitor MPT0G009
por: Hsieh, I-N, et al.
Publicado: (2014)

The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells
por: Chen, M-C, et al.
Publicado: (2013)

Optimization and Development of Selective Histone Deacetylase Inhibitor (MPT0B291)-Loaded Albumin Nanoparticles for Anticancer Therapy
por: Putri, Athika Darumas, et al.
Publicado: (2021)

Histone deacetylase inhibitor MPT0B291 suppresses Glioma Growth in vitro and in vivo partially through acetylation of p53
por: Buyandelger, Batsaikhan, et al.
Publicado: (2020)

A novel action mechanism for MPT0G013, a derivative of arylsulfonamide, inhibits tumor angiogenesis through up-regulation of TIMP3 expression
por: Wang, Chih-Ya, et al.
Publicado: (2014)

Novel histone deacetylase inhibitor MPT0G009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma
por: Chen, Mei-Chuan, et al.
Publicado: (2015)

Anticancer Study of a Novel Pan-HDAC Inhibitor MPT0G236 in Colorectal Cancer Cells
por: Tsai, Feng-Lung, et al.
Publicado: (2023)

A Novel Dual HDAC6 and Tubulin Inhibitor, MPT0B451, Displays Anti-tumor Ability in Human Cancer Cells in Vitro and in Vivo
por: Wu, Yi-Wen, et al.
Publicado: (2018)

A novel class I HDAC inhibitor, MPT0G030, induces cell apoptosis and differentiation in human colorectal cancer cells via HDAC1/PKCδ and E-cadherin
por: Wang, Li-Ting, et al.
Publicado: (2014)

MPT0G066, a novel anti-mitotic drug, induces JNK-independent mitotic arrest, JNK-mediated apoptosis, and potentiates antineoplastic effect of cisplatin in ovarian cancer
por: Huang, Han-Li, et al.
Publicado: (2016)

Targeting Autophagy by MPT0L145, a Highly Potent PIK3C3 Inhibitor, Provides Synergistic Interaction to Targeted or Chemotherapeutic Agents in Cancer Cells
por: Chen, Chun-Han, et al.
Publicado: (2019)

The novel histone de acetylase 6 inhibitor, MPT0G211, ameliorates tau phosphorylation and cognitive deficits in an Alzheimer’s disease model
por: Fan, Sheng-Jun, et al.
Publicado: (2018)

TIMP3 expression associates with prognosis in colorectal cancer and its novel arylsulfonamide inducer, MPT0B390, inhibits tumor growth, metastasis and angiogenesis
por: Huang, Han-Li, et al.
Publicado: (2019)

TIMP3 expression associates with prognosis in colorectal cancer and its novel arylsulfonamide inducer, MPT0B390, inhibits tumor growth, metastasis and angiogenesis: Erratum
por: Huang, Han-Li, et al.
Publicado: (2021)

An oral quinoline derivative, MPT0B392, causes leukemic cells mitotic arrest and overcomes drug resistant cancer cells
por: Chao, Min-Wu, et al.
Publicado: (2017)

MPT0G413, A Novel HDAC6-Selective Inhibitor, and Bortezomib Synergistically Exert Anti-tumor Activity in Multiple Myeloma Cells
por: Huang, Fang-I, et al.
Publicado: (2019)

A novel dual HDAC and HSP90 inhibitor, MPT0G449, downregulates oncogenic pathways in human acute leukemia in vitro and in vivo
por: Wu, Yi-Wen, et al.
Publicado: (2021)

Combining an Autophagy Inhibitor, MPT0L145, with Abemaciclib Is a New Therapeutic Strategy in GBM Treatment
por: Hsieh, Tsung-Han, et al.
Publicado: (2021)

Anticancer activity of MPT0G157, a derivative of indolylbenzenesulfonamide, inhibits tumor growth and angiogenesis
por: Huang, Yen-Chia, et al.
Publicado: (2015)

The anticancer effects of MPT0G211, a novel HDAC6 inhibitor, combined with chemotherapeutic agents in human acute leukemia cells
por: Tu, Huang-Ju, et al.
Publicado: (2018)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

Effect of 3-subsitution of quinolinehydroxamic acids on selectivity of histone deacetylase isoforms
por: Mehndiratta, Samir, et al.
Publicado: (2020)

Synthesis and biological evaluation of C-4 substituted phenoxazine-bearing hydroxamic acids with potent class II histone deacetylase inhibitory activities
por: Chu, Jung-Chun, et al.
Publicado: (2023)

Discovery of potent histone deacetylase inhibitors with modified phenanthridine caps
por: Fan, Wenli, et al.
Publicado: (2021)

MPT0B098, a Microtubule Inhibitor, Suppresses JAK2/STAT3 Signaling Pathway through Modulation of SOCS3 Stability in Oral Squamous Cell Carcinoma
por: Peng, Hsuan-Yu, et al.
Publicado: (2016)

Novel microtubule inhibitor MPT0B098 inhibits hypoxia-induced epithelial-to-mesenchymal transition in head and neck squamous cell carcinoma
por: Tsai, I-Ting, et al.
Publicado: (2018)

In silico and in vitro identification of inhibitory activities of sorafenib on histone deacetylases in hepatocellular carcinoma cells
por: Liu, Tsang-Pai, et al.
Publicado: (2017)

MPT0G612, a Novel HDAC6 Inhibitor, Induces Apoptosis and Suppresses IFN-γ-Induced Programmed Death-Ligand 1 in Human Colorectal Carcinoma Cells
por: Chen, Mei-Chuan, et al.
Publicado: (2019)

Upgrades of the Nuclotron Injector for Acceleration of Ions with Z/A = 0.28
por: Baldin, A, et al.
Publicado: (1996)

Moderate strength (0.23–0.28 T) static magnetic fields (SMF) modulate signaling and differentiation in human embryonic cells
por: Wang, Zhiyun, et al.
Publicado: (2009)

Histone deacetylase inhibitors in Hodgkin lymphoma
por: Buglio, Daniela, et al.
Publicado: (2010)

Thioester derivatives of the natural product psammaplin A as potent histone deacetylase inhibitors
por: Baud, Matthias G J, et al.
Publicado: (2013)

Discovery of indole-3-butyric acid derivatives as potent histone deacetylase inhibitors
por: Chen, Yiming, et al.
Publicado: (2021)

The histone deacetylase inhibitor panobinostat is a potent antitumor agent in canine diffuse large B-cell lymphoma
por: Dias, Joana N.R., et al.
Publicado: (2018)

Metabolism of Histone Deacetylase Proteins Opsonizes Tumor Cells to Checkpoint Inhibitory Immunotherapies
por: Dent, Paul, et al.
Publicado: (2019)

Histone Deacetylase Inhibitory and Cytotoxic Activities of the Constituents from the Roots of Sophora Pachycarpa
por: Soltani, Saba, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jahddokoou0tnbs78aidmj4l3k